Search clinical trials for: PF-06651600 Maintenance Dose #3

Total 672 results

Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Healthy Participants

United States
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Healthy Participants

China
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Pfizer

Completed

Bioavailability Study Of PF-06651600 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy

Belgium
Pfizer

Recruiting

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Healthy Volunteers

United States
Pfizer

Completed

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

Healthy Volunteers

Belgium
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Pfizer

Completed

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

Healthy Volunteers | Pharmacokinetics | Adult

Belgium
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

PF-06651600 Taste Study.

Healthy Participants

Belgium
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Healthy Volunteers

United States
AstraZeneca

Terminated

Open-label Extension Study of Brazikumab in Crohn's Disease (INTREPID OLE)

Crohn's Disease | IBD

United States, Taiwan, Poland, Germany, South Africa
AstraZeneca

Terminated

Open-label Extension Study of Brazikumab in Ulcerative Colitis (Expedition)

Ulcerative Colitis

Italy, United States, Taiwan, Germany, Poland, Israel, Puerto Rico, Czechia, South Africa, Japan, Korea, Republic of
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Pfizer

Active, not recruiting

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA (Allegro2a)

Alopecia Areata

United States, Australia, Canada, Poland
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | COPD | Chronic Obstructive Airway Disease

Germany
Pfizer

Completed

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Rheumatoid Arthritis

United States, Poland, Serbia, Slovakia, Czechia, Georgia, Germany, Bulgaria, Hungary
Pfizer

Completed

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

Ocular Hypertension | Primary Open-Angle Glaucoma

United States
Pfizer

Completed

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Active Non-segmental Vitiligo

Spain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
Washington University School of Medicine
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Childhood Obesity Treatment: A Maintenance Approach (COMPASS)

Childhood Obesity | Childhood Overweight

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Rutgers, The State University of New Jersey
Centers for Disease Control and Prevention

Completed

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

Violence | Helping Behavior | Sexual Assault and Rape | Assaultive Behavior

United States
Pfizer

Completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Rheumatoid Arthritis

Czechia, Hungary, Spain, Poland, Canada, Bulgaria, Chile, Georgia, Slovakia, Ukraine
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
Pfizer

Completed

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Healthy Subjects

Belgium
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Galapagos NV

Completed

This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects

Healthy | Elderly

Belgium
Pfizer
Thrombolysis In Myocardial Infarction (TIMI)

Recruiting

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

Heart Failure

United States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, Germany, United Kingdom, Poland
Pfizer

Active, not recruiting

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

Healthy Participants

United States
Pfizer

Completed

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States

3

Subscribe